文献速递炎症性肠病

炎症性肠病患者组织学缓解与死亡率:全国性队列研究

Histologic Remission and Mortality in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-11-13

瑞典全国性队列研究显示,IBD患者组织学炎症与2年全因死亡率升高相关(aHR 1.45,95%CI 1.30-1.61),临床活动亦相关(aHR 3.35,95%CI 3.21-3.49);即使临床静止,组织学炎症仍增加死亡风险(aHR 1.42,95%CI 1.08-1.87)。

要点

  • 组织学炎症者2年全因死亡率高于组织学缓解者(aHR 1.45)。
  • 临床活动IBD患者2年全因死亡率显著增加(aHR 3.35)。
  • 临床静止但组织学炎症者死亡风险仍升高(aHR 1.42)。

核心结论

  • 组织学炎症和临床活动均与IBD患者全因死亡率增加相关,改善疾病控制或可降低死亡风险。

研究设计与样本

  • 瑞典全国性队列研究,组织学分析纳入63358例1969-2017年诊断的IBD患者,临床活动分析纳入102352例1969-2020年诊断的患者。
  • 采用病因特异风险模型估计指数日期后2年内死亡率的调整风险比(aHR)及95%CI。

主要发现

  • 组织学炎症者2年全因死亡率为121.0/万人年,组织学缓解者为64.8/万人年(aHR 1.45;95%CI 1.30-1.61)。
  • 组织学炎症的死亡风险增加见于所有IBD亚型:克罗恩病(aHR 1.42;95%CI 1.16-1.73)、溃疡性结肠炎(aHR 1.44;95%CI 1.26-1.65)、未分类IBD(aHR 1.56;95%CI 1.01-2.41)。
  • 临床活动IBD者2年全因死亡率为352.6/万人年,临床静止者为106.3/万人年(aHR 3.35;95%CI 3.21-3.49)。
  • 临床静止IBD患者中,组织学炎症仍与2年全因死亡率增加相关(aHR 1.42;95%CI 1.08-1.87)。

临床怎么用

  • IBD管理除控制临床症状外,应关注组织学炎症的评估与控制,以可能降低死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Inflammatory bowel disease (IBD) is associated with increased mortality risk. However, whether this risk is influenced by histologic and clinical activity remains uncertain. METHODS: A nationwide cohort study in Sweden. We compared mortality rates linked to histologic inflammation in 63,358 patients diagnosed with IBD 1969-2017 and to clinical activity in 102,352 patients diagnosed 1969-2020. The adjusted hazard ratio (aHR) of mortality within 2 years after index date (ie, date of histologic/clinical activity) was estimated using cause-specific hazard model, with 95% confidence intervals (CIs). RESULTS: A higher 2-year all-cause mortality was observed after histologic inflammation than after histologic remission (mortality rate: 121.0 vs 64.8 per 10,000 person-years; aHR, 1.45; 95% CI, 1.30-1.61). This excess risk was observed in all IBD subtypes: Crohn's disease (aHR, 1.42; 95% CI, 1.16-1.73), ulcerative colitis (aHR, 1.44; 95% CI, 1.26-1.65), and IBD unclassified (aHR, 1.56; 95% CI, 1.01-2.41). Clinically active IBD was also associated with an increased 2-year all-cause mortality compared to quiescent IBD (mortality rate: 352.6 vs 106.3 per 10,000 person-years; aHR, 3.35; 95% CI, 3.21-3.49). Even in patients with clinically quiescent IBD, histologic inflammation was associated with an increased 2-year all-cause mortality (aHR, 1.42; 95% CI, 1.08-1.87). CONCLUSIONS: Both histologic inflammation and clinical activity of IBD were associated with increased all-cause mortality, suggesting that improved disease control may reduce mortality risk in IBD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sun J, Mårild K, Bergman D, et al. Histologic Remission and Mortality in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2025. PMID: 41241226. doi:10.1016/j.cgh.2025.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。